Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study

Baltazar GomezMancilla, Matthew N Meriggioli*, Angela Genge, Ronenn Roubenoff, Pascal Espié, Cyrielle Dupuy, Nicole Hartmann, Nicole Pezous, Arvind Kinhikar, Mia Tichy, Annie Dionne, John Vissing, Henning Andersen, Benedikt Schoser, Andreas Meisel, Berit Jordan, Farida Devlikamova, Irina Poverennova, Fatima Stuchevskaya, Thy-Sheng LinJames S Rush, Peter Gergely

*Corresponding author for this work
4 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology